An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Trial Profile

An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CPI 613 (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Cornerstone Pharmaceuticals
  • Most Recent Events

    • 23 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top